{"id":4035,"date":"2025-03-31T18:11:56","date_gmt":"2025-03-31T18:11:56","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/gabapentin-txt\/"},"modified":"2025-03-31T18:11:56","modified_gmt":"2025-03-31T18:11:56","slug":"gabapentin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/gabapentin-txt\/","title":{"rendered":"Gabapentin.txt"},"content":{"rendered":"

Gabapentin <\/h1>\n

CLINICAL USE <\/H3>
\nAnti-epileptic:Adjunctive treatment of partial seizures with or without secondary generalisationNeuropathic pain Trigeminal neuralgia (unlicensed)

DOSE IN NORMAL RENAL FUNCTION <\/H3>300 mg on day 1; 300 mg twice daily on day 2; 300 mg 3 times daily on day 3; then increased according to response to 1.2 g daily (in 3 divided doses)If necessary may be further increased in steps of 300 mg daily to a maximum 3.6 g dailyUsual range 0.9\u20133.6 g daily in 3 divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :171.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :<3<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : \u2248100<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.7<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :5\u20137\/52

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201360 Start at low dose and increase dose according to response15\u201330 Start at low dose and increase dose according to response<15 300 mg on alternate days or 100 mg at night initially, increase according to tolerability

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Probably dialysed. Dose as in GFR<15 mL\/min. <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Loading dose of 300\u2013400 mg in patients who have never received gabapentin. Maintenance dose of 100\u2013300 mg after each\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : session and increase according to tolerability.
  • HDF\/high flux &nbsp :Dialysed. Loading dose of 300\u2013400 mg in patients who have never received gabapentin. Maintenance dose of 200\u2013300 mg after each\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : session and increase according to tolerability.
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=15\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAntacids: reduce absorption\n
  • Antidepressants: antagonism of anticonvulsive effect (convulsive threshold lowered)\n
  • Antimalarials: possibly increased risk of convulsions with chloroquine and hydroxychloroquine; anticonvulsant effect antagonised by mefloquine

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>For neuropathic pain in renal patients do not give loading doseCan cause false positive readings with some urinary protein testsFor neuropathic pain or restless legs in patients with moderate to severe renal impairment, start with 100 mg daily and increase according to responseCan be used to treat dialysis itch.
    \n","protected":false},"excerpt":{"rendered":"

    Gabapentin CLINICAL USE Anti-epileptic:Adjunctive treatment of partial seizures with or<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4035","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4035"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4035\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}